Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Two-year extension study of FTY720 versus MMF with tacrolimus and steroids in adult de novo renal transplant recipients
2005-000350-69Phase 3Terminated
- Sponsor
- Novartis
- Start
- May 2006
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in kidney transplant comparing FTY720 + tacrolimus + corticosteroids with CellCept + tacrolimus + corticosteroids (2 arms). Primary endpoint: Composite efficacy and safety endpoint. Started May 2006; status: terminated.
02
Drugs
fingolimodmycophenolate mofetiltacrolimuscorticosteroids
03
Conditions
kidney transplant
Beyond the preview
Go deeper on 2005-000350-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000350-69.